Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic challenges in pathologic staging of renal cell carcinoma following systemic immunotherapy.

American journal of clinical pathology·2026
Same author

Immunodominance Hierarchy of Endogenous BBN963 Bladder Cancer Antigens Remains Stable Under Anti-PD1 and Anti-CTLA4 Immunotherapy.

bioRxiv : the preprint server for biology·2026
Same author

Blinded by the Smoke: Are We Ignoring a Key Modifier of Response in NMIBC Trials?

The Journal of urology·2026
Same author

Computational pathology in bladder cancer: A scoping review.

Bladder cancer (Amsterdam, Netherlands)·2026
Same author

DeCAF defines clinical fibroblast subtypes and multidimensional tumor-stroma crosstalk shaping prognosis and immunotherapy response.

Cell reports. Medicine·2026
Same author

Computational design of orthogonal TCR α/β interfaces for dual-TCR therapeutics.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jun 15, 2025

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.6K

Renal Cell Carcinoma: A Review.

Tracy L Rose1,2, William Y Kim1,2,3,4

  • 1Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill.

JAMA
|August 28, 2024
PubMed
Summary

Renal cell carcinoma (RCC) is a common cancer often found incidentally. Early-stage treatments like surgery offer high survival, while new therapies improve outcomes for advanced RCC.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.5K
In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses
09:31

In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses

Published on: March 30, 2015

8.9K

Related Experiment Videos

Last Updated: Jun 15, 2025

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.6K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.5K
In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses
09:31

In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses

Published on: March 30, 2015

8.9K

Area of Science:

  • Oncology
  • Urology

Background:

  • Renal cell carcinoma (RCC) is a significant global health concern, ranking as the sixth most common cancer in US males and ninth in US females.
  • Clear cell RCC, the predominant subtype, involves the von Hippel Lindau (VHL) gene.
  • Many RCC cases (37%-61%) are incidentally detected via imaging, with 70% diagnosed at early stage I.

Purpose of the Study:

  • To review the incidence, diagnosis, and treatment landscape of renal cell carcinoma.
  • To highlight advancements in managing both early-stage and metastatic RCC.

Main Methods:

  • Review of epidemiological data on RCC incidence and mortality.
  • Analysis of current treatment modalities for localized and advanced RCC.
  • Synthesis of survival outcomes associated with various therapeutic approaches.

Main Results:

  • RCC incidence is rising, yet mortality rates are declining.
  • Partial nephrectomy for tumors <4 cm yields >94% 5-year cancer-specific survival.
  • Advanced RCC treatments, including immune checkpoint inhibitors, show response rates of 42%-71%.

Conclusions:

  • Early-stage RCC is often incidentally diagnosed and effectively treated with surgery or ablative techniques.
  • Emerging therapies offer improved prognoses for patients with metastatic renal cell carcinoma.